-
FDA Weighs Expanding Access to a Dozen Peptides Through Compounding List
The FDA is evaluating whether to add roughly a dozen peptides to its bulk drug compounding list, a move that could broaden legitimate access to these compounds through licensed compounding pharmacies.
-
FDA-Approved Peptide Therapies Offer New Options for Weight Management
The FDA has approved peptide-based medications for weight loss, giving patients and doctors additional evidence-backed tools to address obesity and related health concerns.
-
Cutting Through the Hype: The Peptide Therapies That Have Earned FDA Approval
While many peptides circulate as unregulated trend products, a growing number have cleared rigorous FDA review and are available as approved treatments for diabetes, weight management, and other conditions.
-
Review Highlights the Expanding Promise of Therapeutic Peptides
A new scientific review in Signal Transduction and Targeted Therapy surveys how far therapeutic peptides have come and where the field is headed next, underscoring their growing role in modern medicine.
-
C-Peptide Gains Momentum as a Key Measure for Type 1 Diabetes Trials
Researchers and advocacy groups are championing C-peptide as a meaningful clinical trial endpoint for type 1 diabetes, a shift that could speed up the development of new therapies that preserve insulin-producing cells.
-
FDA Continues to Support Peptide-Based Weight Loss Treatments
Recent coverage highlights the FDA’s ongoing approval pathway for peptide-based weight management therapies, reflecting growing regulatory confidence in this class of treatments.
-
FDA-Approved Peptide Therapies Offer New Hope for Weight Management
Peptide-based medications continue to gain regulatory traction in the U.S., giving patients and physicians more FDA-sanctioned options for weight management support.
-
Merck Advances Oral Peptide Candidate Into Phase 1 Trial Using Cyprumed’s Delivery Technology
Merck has initiated a Phase 1 clinical trial for an oral peptide therapeutic developed using Cyprumed’s oral delivery technology, marking a step forward in making peptide treatments more accessible without injections.
-
New Clinical Trial Launches to Study Innovative Weight-Loss Peptide Combination for Type 2 Diabetes
A new two-year study will explore whether combining eloralintide with tirzepatide offers enhanced benefits for weight management in adults with obesity and type 2 diabetes. The trial represents continued innovation in peptide-based metabolic treatments.
-
FDA Approves Foundayo™, Eli Lilly’s Convenient New Once-Daily GLP-1 Pill for Weight Loss
The FDA has approved Eli Lilly’s Foundayo™ (orforglipron), a groundbreaking oral GLP-1 medication for weight loss that can be taken at any time of day without food or water restrictions, offering patients a simpler alternative to injectable treatments.